Overexpression of the β-catenin binding domain of cadherin selectively kills colorectal cancer cells

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 229-237

  Pierce, Michael ^a   Wang, Chunwei ^a   Stump, Mark ^a   Kamb, Alexander ^a,b  

^a Deltagen Proteomics Incorporated   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

catenin; Cadherin; Cell lethal; Drug target; Tcf4

Indexed keywords

BETA CATENIN; CADHERIN; PROTEIN CAD5CD; PROTEIN INHIBITOR; PROTEIN TCFDN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ANTIGENS, CD; APOPTOSIS; BETA CATENIN; BINDING SITES; CADHERINS; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0141746242     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11372     Document Type: Article

References (44)

1. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
2. Morin PJ. β-Catenin signaling and cancer. Bioessays 1999;21:1021-30.
3. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
4. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
5. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
6. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7.
7. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
8. Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW. The β-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000;60:1671-6.
9. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated transactivation. J Cell Sci 1999;112:1237-45.
10. Sadot E, Simcha I, Shtutman M, Ben-Ze'ev A, Geiger B. Inhibition of β-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci USA 1998;95:15339-44.
11. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY. Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription. J Cell Biol 2001;152:87-96.
12. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996;93:7950-4.
13. Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M, Takeichi M. Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells. Oncogene 1995;11:2547-52.
14. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ, Pignatelli M, Bodmer WF. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the mitogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA 1999;96:2316-21.
15. Band V, Sager R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci USA 1989;86:1249-53.
16. Wheatley W, Pierce M, Rebentisch M, Endo M, Peterson I, Stump M, Kamb A. Genetic selection for modulators of the MAP kinase and beta-catenin growth control pathways in mammalian cells. Biochem Genet 2002;40:359-78.
17. Stump M, Di Sera L, Rebentisch M, Endo M, Pierce M, Kamb A. An automated system for screening retroviral expression constructs in microplate format. J Biomol Screen 2002;7:275-80.
18. Pierce M, Wang C, Rebentisch M, Endo M, Stump M, Kamb A. A homogeneous microplate assay for agents that kill mammalian tissue culture cells. J Biomol Screen 2003;8:283-90.
19. Kamb A, Ramaswami M: A simple method for statistical analysis of intensity differences in microarray-derived gene expression data. BMC Biotechnol 2001;1:1-8.
20. Sawada S, Littman DR. Identification and characterization of a T cell-specific enhancer adjacent to the murine CD4 gene. Mol Cell Biol 1991;11:5506-15.
21. Gradl D, Kuhl M, Wedlich D. The Wnt/Wg signal transducer β-catenin controls fibronectin expression. Mol Cell Biol 1999;19:5576-87.
22. Koshland DE Jr. The era of pathway quantification. Science 1998;280:852-3.
23. Elson A. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Oncogene 1999:18:7535-42.
24. Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakata K, Watanabe K, Ishii N, Kimura N, Nagataki S. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 1992;84:1349-54.
25. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
26. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyoma S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of β-catenin. J Biol Chem 1998;273:10823-6.
27. Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, Akiyama T. Axin, an inhibitor of the Wnt signaling pathway, interacts with β-catenin, GSK-3β and APC and reduces the β-catenin level. Genes Cells 1998;3:395-403.
28. Sasaki CY, Lin H, Morin PJ, Longo DL. Truncation of the extracellular region abrogates cell contact but retains the growth-suppressive activity of E-cadherin. Cancer Res 2000;60:7057-65.
29. Zhu AJ, Watt FM. Expression of a dominant negative cadherin mutant inhibits proliferation and stimulates terminal differentiation of human epidermal keratinocytes. J Cell Sci 1996;109:3013-23.
30. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
31. Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, Logtenberg T, Clevers H. Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science 1999;285:1923-6.
32. Levanon D, Goldstein R, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paroush Z, Groner Y. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci USA 1998;95:11590-5.
33. Brannon M, Brown J, Bates R, Kimelmann D, Moon R. XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development. Development 1999;126:3159-70.
34. Green D, Roh H, Pippin J, Drebin J. β-Catenin antisense treatment decreases β-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res 2001;101:16-20.
35. Li H, Liu L, David M, Whitehead C, Chen M, Fetter J, Sperl G, Pamukcu R, Thompson W. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve β-catenin and cyclin D1 down-regulation. Biochem Pharm 2002;64:1325-36.
36. Roh H, Green D, Boswell C, Pippin J, Drebin J. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001;61:6563-8.
37. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203-7.
38. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for non autonomous regulation of cell fate in a self-renewing system. Genes Dev 1996;10:985-96.
39. Lipinski K, Djeha A, Ismail T, Mountain A, Young L, Wrighton C. High-level, β-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther 2001;4:365-71.
40. Kwong K, Zou Y, Day C, Hung M. The suppression of colon cancer cell growth in nude mice by targeting β-catenin/TCF pathway. Oncogene 2002;21:8340-6.
41. Huber AH, Weis WI. The structure of the β-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by β-catenin. Cell 2001;105:391-402.
42. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 1998;395:710-3.
43. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson A, Guo L, Sakamoto D, Caothien R, Fuller J, Reinhard C, Garcia P, Randazzo F, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 2001;98:14973-8.
44. Wang H, Wang J, Xiao S, Haydon R, Stoiber D, He T, Bissonnette M, Hart J. Elevated protein expression of cyclin D1 and FRA-1 but decreased expression of c-myc in human colorectal adenocarcinomas overexpressing β-catenin. Int J Cancer 2002;101:301-10.